| Literature DB >> 24472435 |
Shahram Baraz, Kourosh Zarea1, Hajie Bibi Shahbazian, Seyed Mahmoud Latifi.
Abstract
BACKGROUND: Diabetic Peripheral Neuropathy is one of the most prevalent complications of diabetes mellitus. The development and progression of such complications are responsible for much of the morbidity and mortality. The purpose of this study was to evaluate the effectiveness of Semmes-Weinstein monofilament ten gram in 3, 4, eight and ten points in the screening of diabetic peripheral neuropathy in patients with diabetes mellitus.Entities:
Year: 2014 PMID: 24472435 PMCID: PMC3922886 DOI: 10.1186/2251-6581-13-19
Source DB: PubMed Journal: J Diabetes Metab Disord ISSN: 2251-6581
Demographics variables in the patients
| Age | 8.95 ± 55.71 |
| Sex: Male | 47(31.3) |
| Female | 103(68.7) |
| Duration of disease | 6.1 ±7.7 |
| FBS | 72.66 ±169.92 |
| HbA1c | 3.96 ± 8.26 |
| CHLO | 44.10 ± 182.31 |
| TG | 54.87 ± 127.49 |
| HDL | 12.24 ± 47.21 |
| LDL | 34.09 ± 100.21 |
| BMI | 4.85 ± 27.45 |
| Weight | 8.99 ± 55.35 |
Sensitivity and specificity of the 10 g monofilament according to the number of insensate sites
| Monofilament ≥1/8* | 51.3 | 73 |
| Monofilament ≥ 2/8† | 46.2 | 74.8 |
| Monofilament ≥4/8‡ | 38.5 | 87.4 |
*Minimum of 8 point 1 point reported by patients as a numbness site.
†Minimum of 8 point 2 point reported by patients as numbness site.
‡Minimum of 8 point 4 point reported by patients as numbness site.
Sensitivity and specificity of the 10 g monofilament according to the number of insensate sites
| Monofilament ≥1/6* | 53.8 | 73.9 |
| Monofilament ≥ 2/6† | 43.6 | 79.3 |
| Monofilament ≥3/6‡ | 35.9 | 84.7 |
*Minimum of 6 point 1 point reported by patients as a numbness site.
†Minimum of 6 point 2 point reported by patients as numbness site.
‡Minimum of 6 point 3 point reported by patients as numbness site.
Sensitivity and specificity of the 10 g monofilament according to the number of insensate sites
| Monofilament ≥1/20* | 64.1 | 64 |
| Monofilament ≥ 2/20† | 61.5 | 64 |
| Monofilament ≥10/20‡ | 30.8 | 89.2 |
*Minimum of 20 point 1 point reported by patients as a numbness site.
†Minimum of 20 point 2 point reported by patients as numbness site.
‡Minimum of 20 point 10 point reported by patients as numbness site.
Sensitivity and specificity of the 10 g monofilament according to the number of insensate sites in 16points according to insensate sites
| Monofilament ≥1/16* | 61.5 | 77.5 |
| Monofilament ≥ 2/16† | 59 | 79.3 |
| Monofilament ≥8/16‡ | 38.5 | 95.5 |
*Minimum of 16 point 1 point reported by patients as a numbness site.
†Minimum of 16 point 2 point reported by patients as numbness site.
‡Minimum of 16 point 8 point reported by patients as numbness site.
Sensitivity and specificity according to methodologies used to assess insensitivity
| Monofilament ≥1/6 | 53.8 | 73.9 |
| Monofilament ≥1/8 | 51.3 | 73 |
| Monofilament ≥1/16 | 61.5 | 77.5 |
| Monofilament ≥1/20 | 64.1 | 64 |
| NDS | 94.9 | 91 |
| 128 Hz tuning forka | 84.6 | 43.2 |
a≥1 of the two sites tested was considered positive.